AVDL Avadel Pharmaceuticals plc - Am

9.84
-0.06  -1%
Previous Close 9.90
Open 9.92
Price To book 6.93
Market Cap 407.14M
Shares 41,376,000
Volume 121,980
Short Ratio 2.58
Av. Daily Volume 172,303

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved June 3, 2013.
Bloxiverz (neostigmine methylsulfate)
Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery
Announced approval May 2 2016
Akovaz
Hypotension
Phase 3 SPA agreed on - October 2016. Initiation of dosing announced December 16, 2016.
Micropump Sodium Oxybate
Excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy
Approved June 30 2014.
VAZCULEP (phenylephrine hydrochloride)
Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia
Approved Jun 3 2013
Bloxiverz (neostigmine methylsulfate)
Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery

SEC Filings

  1. 8-K - Current report 17874231
  2. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17874201
  3. 8-K - Current report 17853628
  4. 8-K - Current report 17839481
  5. 8-K - Current report 17832900
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 17831628
  7. 8-K - Current report 17824441
  8. 8-K - Current report 17800653
  9. DEF 14A - Other definitive proxy statements 17800600
  10. 8-K - Current report 17780228